The FAIR project has reached another significant milestone with the start of a phase I clinical trial for a groundbreaking therapeutic intervention for respiratory infections.
The FAIR project continues to drive innovation in respiratory infection therapies, and the recent ERS online course, “Virtual School of Nebulization of Drugs for Treatment of Respiratory Infections and Disease,” provided valuable insights into the latest advancements in nebulized drug delivery.
Flagellin aerosol therapy as an immunomodulatory adjunct to the antibiotic treatment of drug-resistant bacterial pneumonia (FAIR) will present a symposium at this year’s ERS Congress, from 7-11 September, in Vienna, Austria.
FAIR had the great opportunity to present its objectives and preliminary findings in a full symposium at the European Respiratory Society (ERS) Congress in Vienna, Austria from September 7-11, 2024.
The FAIR project, which aimed to pave the way for the first-in-human phase I clinical trial with nebulized flagellin, is now entering the final stage after a successful 18 months of progress.
- Listen to the recording of first webinar of FAIR
- FAIR project makes substantial progress despite pandemic pitfalls
- FAIR project study looks at factors which influence patient/clinician attitudes towards new treatment
- FAIR: an EU funded project to investigate new treatments for antibiotic-resistant pneumonia